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ABSTRACT
The prodromal stage of Alzheimer’s Disease, amnestic mild cognitive
impairment, is characterized by subjective and objective memory impairment beginning
with episodic memory. Few treatments have been identified to effectively slow disease
progression to dementia. Meditation is an emerging novel treatment to improve deficits in
subjects with these progressive cognitive impairments. Meditation and other novel
treatments are critical for prolonging patients’ independence, reducing caregiver burden,
and healthcare costs. This study will examine the effectiveness of an eight-week
intervention using two meditation methods and two control groups on cognition and
mood in participants with amnestic mild cognitive impairment. The primary outcome is
episodic memory. Secondary outcomes include verbal fluency, executive function,
working memory, and mood symptoms. We believe meditation interventions are lowcost, safe, easily implemented interventions that could improve cognition and mood
symptoms in patients with amnestic mild cognitive impairment through induced changes
within the Default Mode Network.
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CHAPTER ONE-INTRODUCTION
I. Alzheimer’s Disease
I.a Epidemiology
Alois Alzheimer first described Alzheimer’s Disease in 1906 while presenting a
51 year old patient with progressive cognitive decline.1 Now, the disease bearing his
name affects 36 million people worldwide and is the most common cause of dementia.2
This number is projected to increase to 115.4 million by 2050 due to the globally
increasing population over 65. Additionally, it is suggested that half of people with AD
are never diagnosed, so the scope is likely much greater than stated. AD most commonly
presents in the seventh decade of life, and two-thirds of cases are in women. Earlier-onset
cases are less common and are often due to familial genetic mutations.1 Its prodromal
state, amnestic mild cognitive impairment, is the target of many pharmaceutical and nonpharmaceutical interventions aimed at slowing cognitive decline and preserving
independence. This study focuses on this population.
I.b Risk Factors
While age is the greatest risk factor for AD; family history and the presence of the
APOE4 gene are other non-modifiable risk factors.2 Known modifiable risk factors
include cardiovascular disease, hypertension, hyperlipidemia, sedentary lifestyle, obesity,
smoking, diabetes, insomnia, and fewer years of education. Growing evidence from the
literature suggests depression, anxiety, and chronic stress are also risk factors for the
disease.3
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I.c Diagnosis of Cognitive Impairments
AD is a progressive neurodegenerative disease with hallmark neuropathology.4
This includes -amyloid protein fragments causing plaques to accumulate on neurons’
exterior while tau proteins accumulate within neurons, leading to dysfunction,
deregulation, and neuronal death. While these biomarkers of AD are well established and
correlate to clinical severity, AD remains a clinical diagnosis, for which the National
Institute on Aging and Alzheimer’s Association proposed new diagnostic criteria in
2011.2 The new guidelines divide AD into three separate stages that are described below:
preclinical AD, mild cognitive impairment due to AD, and dementia due to AD. This
study will adapt these criteria to the definition and diagnosis of aMCI.
I.c.i Preclinical AD
Preclinical AD features positive biomarkers including increased levels of tau or ptau in cerebral spinal fluid, decreased cerebral spinal fluid ab 1-42 levels,5 or changes on
magnetic resonance imaging (MRI), single-photon emission computed tomography
(SPECT) and positron emission tomography (PET) imaging.2,6,7 However, the patient
exhibits no subjective or objective memory complaints. The biomarkers have been found
up to twenty years before a person exhibits memory symptoms.2 Due to the lack of
subjective or objective memory impairments, preclinical AD is largely a diagnostic
category utilized by research studies.
I.c.ii aMCI
aMCI features subjective and objective impairments in one or more areas of
memory, learning, and recall that do not preclude the person from functioning
independently.2 Of all aMCI cases, 50% progress to dementia within 3-4 years. While
2

symptoms vary, many individuals with aMCI first experience a loss of ability to
remember newly learned information, often described as short term memory loss.2 In this
study, individuals with aMCI were selected because of the proposed effectiveness of
disease modifying treatments administered before the cognitive decline has advanced into
dementia.1,2 Additionally, treatment in this group aims to prolong their high quality of life
by preserving independent functioning.
I.c.iii Dementia due to AD
Dementia due to AD is diagnosed when clinical criteria for aMCI progresses to
include impairments in daily functioning, such as the inability to manage finances or
medication.2 Disorientation to time and place, while retaining orientation to person is also
common, as well as problems with planning, judgment, withdrawal, apathy, depression,
and misplacing belongings. Eventually, incapacitation leads to development of secondary
infections, such as aspiration pneumonia or falls, which can lead to death. In the United
States, AD is the sixth leading cause of death across all ages.
I.d Treatment
The Food and Drug Administration has approved five medications for AD, but
none can slow or stop the ultimate disease progression.2 The efficacy of these
medications has been based on delaying a patient’s institutionalization or requirement of
a full time aide by one year. Given that this is the benchmark for pharmaceutical
effectiveness, there remains ample room for behavioral, non-pharmaceutical
interventions, which may delay, or allow compensation for, the disease processes. Drug
development cost, trial longevity, and the blood brain barrier are current barriers to more
effective drug development. Studies have increasingly focused on the possibility of

3

delaying expression of AD clinical symptoms with non-pharmacologic therapies
including meditation, exercise, sleep, yoga, and specialized nutrition.8 These alternative
therapies also primarily aim to delay the decline of cognitive function, preserve
independence, and improve quality of life for patients and their caregivers.
II. Meditation
Meditation is thousands of years old practice traditionally used in religious or
spiritual settings that has more recently been employed in Western cultures to enhance
overall well-being.3 While there are many variations and types of meditation, one uniting
feature is the goal of focused, self-regulation of attention as well as open and accepting
experience of the present moment. Meditation practice aims to engage the mind in goaldirected activity and regulation of attention and awareness while the body is in a
hypometabolic state.9 Meditation interventions have been studied in patients with chronic
pain, fibromyalgia,10 cancer,11 coronary artery disease, and depression on a variety of
outcomes including stress, cognition, attention, anxiety, and depression.8,12 Meditation
has recently been studied as a promising non-pharmaceutical intervention for subjective
cognitive decline, aMCI, AD, and other dementias, though the pathophysiology behind
its effects remains unclear.2-4
II.a Kirtan Kriya Meditation
Kirtan Kriya (KK) meditation is an established, safe, easy to learn, and effective
meditation intervention studied in subjects with and without memory complaints, aMCI,
and AD and other dementias.3 It is the most common meditation intervention in the
literature in subjects with aMCI and AD, and thus one of the meditation interventions for
this study.
4

KK meditation is a simple chanting meditation performed over 12 minutes13
(Appendix A). Chanting meditations focus on the repetition of speech, or mantras, to
produce a meditative state. KK combines the mantra “saa, taa, naa, maa” with repetitive
matched finger movements touching the thumb to the first, second, third, and fourth
fingers in time with the words. The mantra is repeated spoken, whispered, and silently for
two minutes each, then silently, whispered, and spoken for a total of 12 minutes of
practice.
II.b Mindfulness Meditation
Another form of meditation, Mindfulness (MFL), teaches the subject to focus on
the present, while they accept other stimuli that enter the mind, before dismissing them.14
Practitioners focus on a physical element, such as breathing, to help maintain focus and
control of thoughts moving through the body (Appendix B). Mindfulness Based Stress
Reduction (MBSR) is an intensive intervention that requires longer periods of home
meditation practice as well as group meetings.8,15 MBSR has shown positive outcomes on
wellbeing, acceptance of situations,16 improved sleep,17 decreased morning cortisol
levels, and improved executive functioning and working memory18 in subjects with and
without cognitive impairment.
The effects of MBSR in AD and aMCI have been investigated, but the procedure
of MBSR is much more intensive and too dissimilar from the KK protocol for this
proposed study. Instead, this study’s MFL intervention is a brief 12-minute intervention
similar to the KK intervention. To our knowledge, this type of meditation intervention
has never been studied in populations with aMCI. By including a MFL intervention
similar to the KK meditation in time and duration, we aim to explore a possible role for
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other types of brief meditation for people with aMCI. The MFL intervention will have
subjects focus on their breathing, while they direct their thoughts in an L-shaped pattern
through the top of their head and out of their mouth as they exhale.
III. Proposed Mechanism of Action
This study aims to expand on the current literature that has shown that meditation
is an effective and safe intervention for people with aMCI. While this study will not
pursue imaging, it draws from previous results to suggest a pathophysiology behind the
hypotheses of meditation’s impact on a brain with aMCI. Specifically, the default mode
network (DMN) can be modified and strengthened through meditation.
The DMN is a group of anatomically separate regions that show functional
interconnectedness through synchronized patterns of activation, especially at rest,19,20 and
when a person is not engaged in a goal-oriented task.21 The proposed regions of the DMN
include the medial prefrontal cortex (mPFC), posterior cingulate cortex (PCC), anterior
cingulate cortex (ACC), precuneus, inferior parietal cortex, and lateral temporal cortex.2224

The PCC is thought to be the posterior hub that communicates to areas important for

memory encoding, retrieval, and formation like the hippocampus while the mPFC is
thought to be the anterior hub of activity.21
Selective areas of DMN activation are associated with mind wandering,
daydreaming, self-memory, self-reflection, prospective thought, and thinking in the
perspective of others.19-21 The DMN is also shown to be overall more active during tasks
of episodic memory, such as autobiographical thought, which is compromised in aMCI
and AD.23 Concurrently, areas of the DMN are selectively deactivated during processes
requiring attention and concentration. Research has found that experienced meditators
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deactivate the regions of the DMN associated with mind wandering, and have better
performance on measures of attention and concentration.14,25,26 As many daily tasks
involve aspects of simultaneous use of these functions, the DMN is normally partially,
but selectively activated and deactivated.22 Interruptions and deregulations of these
patterns of activation and deactivation are thought to compose the cognitive disturbances
that cause the aMCI and AD symptoms.27
III.a DMN Disruption
DMN disruption is found in AD, and is a target for pharmacological and
alternative therapy interventions.20,28 The patterns of disruption found in AD are so
consistent and specific that it is a proposed biomarker for AD and aMCI studies.19,21
Additionally, abnormal disruption and activation patterns of the DMN are found on
functional-magnetic resonance imaging (fMRI) studies before objective or subjective
memory symptom onset.21,29 It is important to note that it is the deregulation of the DMN
that is thought to cause the impairments of cognition, not just a global increase or
decrease in activity of DMN function. For example, the areas associated with mind
wandering and rumination show increased activation in AD and aMCI, while there is
decreased activation in areas responsible for episodic memory retrieval.23
IV. Statement of the Problem
Currently there are few validated treatments for aMCI. Recent studies have focused
on novel, non-pharmaceutical treatments to delay expression, and potentially progression
of the disease towards AD. Meditation is one such novel intervention under investigation,
with the aim to potentially improve cognitive function and delay institutionalization. The
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current literature on meditation is limited in scope to KK meditation and MBSR in
subjects with aMCI.
The studies reviewed were generally underpowered, used small sample sizes or
limited to pilot or proof of concept studies, and lacked adequate control groups.13,27,30-32
Several studies used active controls, engaging the subjects in a task of passive relaxation
like music or book listening,30,31 or psychoeducation classes.32 While this strategy is
helpful for separating effects unique to meditation compared to passive relaxation or
active control, it does not allow comparison to an inactive control. This study will employ
a wait list control as a way to control for the possible effects of music listening.33
V. Goals and Objectives
V.a Goals
The purpose of this study is to examine the effects of eight-week Kirtan Kriya and
Mindfulness meditation interventions on percent change from baseline performance of
pre- and post-measures of episodic memory, verbal fluency, working memory, executive
function, anxiety, and depression, compared to an active (music listening) and inactive
control. The primary outcome is episodic memory, specifically verbal memory, as it is
classically impaired in aMCI.34,35 The California Verbal Learning Test-II (CVLT-II),36 a
neuropsychological test, will operationalize verbal memory in this study with four
dependent variables: semantic categorization, total learning (trials 1-5), long delayed
recall, and cued long delayed recall.
Secondary outcomes of this study focus on other impairments common in aMCI
including verbal fluency, working memory, executive function, and symptoms of
depression and anxiety. Verbal fluency will be evaluated with phonemic fluency, using
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the letters C, F, and L, as well as semantic (category-animal) fluency.36 Working memory
will be evaluated with the WAIS-IV Digit Span Test, where subjects must recall lists of
numbers both forwards and backwards in sequence.27 Executive function will be
evaluated with the Trails Making Test (TMT) A and B, which evaluates attention span,
task switching ability, and processing speed.37 Two scales validated for use in elderly
populations will be used for evaluation of mood symptoms. Depression symptoms will be
evaluated by the Geriatric Depression Scale (GDS),38 and anxiety symptoms with the
Rating Anxiety in Dementia (RAID) Scale, which is additionally validated in elderly
people with memory impairments and dementia.39
This study will compliment and expand the current literature by comparing KK
and MFL meditation to two controls, one active and one inactive, on neuropsychological
tests that reflect areas most affected by aMCI. Results will shed light on the relative
effectiveness and feasibility of each meditation practice, which will provide impetus for
future research on meditation in aMCI populations. Use of both an active and inactive
control has not been attempted to our knowledge. Additionally, we aim to further validate
meditation as an effective, safe therapy for aMCI and strengthen evidence for the role of
the DMN in aMCI pathophysiology and treatment.
V.b Objectives
1. Compare KK meditation intervention to music listening and wait-list
controls on measures of episodic memory using the CVLT-II.
2. Compare MFL meditation intervention to music listening and wait-list
controls on measures of episodic memory using the CVLT-II.
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3. Compare secondary outcomes of verbal fluency, working memory,
executive function, depression, and anxiety using Animals Fluency, Letter
C, F, and L Fluency, WAIS-IV Digit Span Test, TMT A and B, GDS, and
RAID measures, respectively, amongst all groups.
VI. Hypothesis
Subjects with aMCI are known to have DMN dysfunction,20,27 while meditation is
known to improve DMN function. These improvements in DMN function have been
linked to improve memory performance. Thus, we hypothesized that an eight-week KK
or MFL intervention will improve scores, as determined by percent change from baseline,
on measures of episodic memory, and secondary outcomes of verbal fluency, working
memory, executive function, depression, and anxiety compared to music listening control
and inactive control groups in subjects with aMCI, as a function of improved DMN
functioning. We expect the effect to be greater between the meditation groups and
inactive controls, compared to the effect between the meditation groups and active
control.
VII. Definitions
A. KK—Kirtan Kriya; 12-minute meditation involving the repetitive movement of
fingers to thumb and repetition of phrase “saa, taa, naa, maa” out loud, whispered,
and silently in 2 minute intervals
B. MFL—Mindfulness; Meditation focused on creating and maintaining awareness
of one’s surroundings, especially body, breath, and mind, and accepting thoughts
and intrusions without judgment
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C. CVLT-II—California Verbal Learning Test-II; neuropsychological test of
episodic (verbal) memory, including semantic categorization, immediate recall,
and delayed recall
D. RAID—Rating Anxiety in Dementia; Scale adapted for demented or cognitively
impaired individuals to rate feelings and symptoms of anxiety in daily living
E. GDS—Geriatric Depression Scale; Scale for use in the elderly to rate feelings of
depression, apathy, and risk for harm or self-harm
F. Animals Category Fluency—Measure of semantic fluency; subject names as
many animals as they can in one minute
G. Letter C, F, L Fluency—Measure of phonemic fluency; subjects name as many
words that begin with the letter C, F, or L as they can in separate one minute trials
H. WAIS-IV Digit Span Test—Measure of working memory, specifically mental
flexibility and processing; subjects must recall lists of numbers forwards and
backwards.
I. Trail Making Tests A and B—Measure of frontal executive function, including
attention span, task switching ability, and processing
J. DMN—Default Mode Network; interconnected brain regions that show increased
activity at rest. Includes posterior cingulate cortex, precuneus, anterior cingulate
cortex, inferior parietal cortex, and lateral temporal cortex
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CHAPTER TWO—REVIEW OF THE LITERATURE
I. Introduction: Literature Search Criteria
A systematic literature review was conducted from August 2015 through May
2016 using Ovid (MEDLINE), PubMed@Yale, and relevant bibliographies with the
following key words: mild cognitive impairment, amnestic mild cognitive impairment,
Alzheimer’s Disease, dementia, meditation, mindfulness meditation, mindfulness, Kirtan
Kriya, default mode network, non-pharmaceutical intervention, non-pharmaceutical
cognitive enhancement, neurodegenerative disease, semantic clustering, verbal fluency,
episodic memory, semantic memory, California Verbal Learning Test-II, Trail Making
Tests A and B, phonemic fluency, category fluency, anxiety and depression in MCI,
GDS, RAID, and WAIS-IV Digit Span Test. Articles written in English, using human
subjects, from 1985 until present were reviewed. Additional articles were sourced from
relevant journals’ bibliographies.
II. Review of Meditation Literature
In 2000, aMCI was formally established as the prodromal state of AD dementia.1,2
aMCI has several characteristic impairments that are the focus of this study. First,
episodic memory is affected, including poor acquisition, retention, or consolidation of
information.3 One part of episodic memory is verbal memory, the ability to process,
retrieve, and recall words. Verbal memory deficiencies are characteristic of aMCI and
AD,4,5 and performance on measures of verbal memory can distinguish aMCI from other
MCI subtypes with high specificity and sensitivity.6 For example, people with AD and
aMCI perform similarly on the CVLT-II compared to those with other subtypes of MCI
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or healthy participants.7 Verbal memory, operationalized by the CVLT-II (total learning
trials 1-5, long delayed recall, and cued long delayed recall), is the primary outcome of
this study. Changes in connectivity of various areas of the DMN are a hypothesized
source of the cognitive changes seen in these people.3
Dunn et al. 2014 examined the differences between the DMN of 24 aMCI and 33
non-aMCI subjects using seed-based resting-fMRI.3 The aMCI subjects showed impaired
hippocampal and PCC connectivity when data were analyzed according to memory
testing performance. The researchers found that resting patterns of DMN connectivity can
distinguish between people with aMCI and non-aMCI. Additionally, they suggested that
during episodic memory retrieval subjects with aMCI show dysfunction between the
hippocampus, medial temporal lobe, and PCC, concluding that this dysfunction was
partially responsible for episodic memory impairment in aMCI. This dysfunctional PCC
connectivity was also seen by De Vogelaere et al. 20128 and Wang et al. 2013.9
Collectively, these results suggest that DMN function correlated directly with
participants’ performance on neuropsychological testing. Concurrently, results of Garces
et al. 201410 and Jin, Pelak and Cordes11 also showed that DMN changes on imaging
correlated with deficiencies of memory function, and are detectable before atrophy is
noticeable on structural MRI.
The verbal memory impairments of aMCI are compounded by impairment of
memory retrieval strategies, such as verbal fluency.6 Verbal fluency tasks are measures of
retrieval networks and are specific and sensitive to select for people with aMCI versus
other MCI subtypes. Verbal fluency is operationalized here as timed word retrieval, and
is comprised of phonemic (C,F,L) and category (animals) fluency. 6,7 Mueller et al. 2015
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followed a cohort (n=283) of cognitively healthy people and people with aMCI for six
years, and examined verbal fluency, phonemic switching, and semantic. Results
suggested that individuals who developed aMCI over the following six years had
significantly lower baseline scores on measures of verbal fluency, with most significant
differences seen in phonemic and semantic fluency.
Gardini et al. 2015 conducted a prospective, randomized clinical trial to study the
effect of aMCI-associated changes in the DMN on semantic memory.12 Subjects were 21
people with aMCI and 21 demographically matched, healthy elderly controls. At
baseline, they found that participants with aMCI had evidence of extensive semantic
memory deterioration, which they attributed to increased, deregulated DMN connectivity
as seen on fMRI. The study examined category fluency, word association tasks,
confrontation naming tasks, definition tasks, and reading tasks. The researchers
concluded that semantic and other impairments of aMCI can be correlated, and likely
attributed to maladaptive reorganization of the DMN.
Working memory and executive function are also impaired in patients with
aMCI,13 and are secondary outcomes of this study. Deregulation of the DMN is thought
to impair attention and concentration, leading to deficits in tasks of working memory and
executive function.9 Set shifting ability and working memory are processes modulated
largely by a frontal neural network, and gray matter of the medial PFC and medial
temporal cortex are amongst the regions most affected by MCI-associated atrophy.14
Tsutsumimoto et al. 2015 found an association between gray matter volume and setshifting ability as measured by the TMT A and B in 83 elderly people with MCI.14
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Limitations of this study include its cross-sectional nature, which prevents attributing
findings to causal relationships.
III. KK and MFL Meditation
While there are many forms of meditation practiced worldwide, this study
focuses on mantra meditation (KK), and MFL meditation. Mantras are repeated phrases
that are thought to have associated emotional or cognitive effects.15 The KK intervention
uses the Kundalini yoga mantra of “saa, taa, naa, maa,” which represents beginning, life,
death, and rebirth. While there is philosophical and spiritual meaning behind this mantra,
we will not introduce this to our subjects. To evaluate whether a spiritual connection to a
mantra or meditation is required to produce the described changes, Berkovic-Ohana et al.
2015 showed that repetitive speech, specifically the repetition of the Hebrew word for
“one”, can reduce fMRI blood-oxygen-dependent level (BOLD) activation primarily
centered in areas of the DMN. These results suggest that even subjectively meaningless
repetitive speech can elicit changes in DMN activity, and subjects do not necessarily need
to spiritually relate to, or understand the mantra to exhibit cognitive changes.
III.a Kirtan Kriya—Independent Variable
Kirtan Kriya meditation is the most studied meditation intervention in people with
AD and MCI. KK is a subtype of transcendental meditation, and involves the use of a
mantra with synchronized finger-thumb touching. Newberg et al. 2010 was the first to
use KK meditation in memory-impaired subjects compared to a music listening control
group.16 They used SPECT imaging to examine cerebral blood flow and
neuropsychological tests to examine cognitive function in subjects with memory loss.
Memory impairments ranged from mild and age-associated, to MCI, to diagnosed AD
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dementia. After an eight-week KK intervention, practiced for 12 minutes per day, the KK
meditation subjects showed improved verbal fluency, Trails B, and logical memory
compared to music listening control, but only verbal fluency reached statistical
significance, with 14% improvement from baseline scores for KK and 3% improvement
from baseline scores for music listening.
On SPECT imaging during meditation, KK subjects with memory impairments
had significantly decreased prefrontal cortex blood flow compared to the music listening
group.16 These results are similar to those of De Vogelaere et al. 2012,8 who found that
subjects with aMCI had increased prefrontal cortex activity at rest compared to
cognitively healthy controls. Together, these results suggest that the aMCI DMN is more
active at rest than in cognitively healthy people, while meditation enhances the ability to
selectively decrease the activity of a brain at rest. Drawbacks of the Newberg et al. 2010
study include small sample size because it was a pilot study (total n=15).16 The study also
lacked an inactive control, and therefore effects of music listening cannot be excluded as
a confounder, decreasing the effect size of the KK group outcomes. Finally, this study
included participants with a range of memory impairments, from age related memory
decline to known AD dementia, and therefore was not an optimally homogeneous, aMCI
population.
III.b Mindfulness—Independent Variable
Two key tenets of MFL meditation are focusing on the present, and accepting
one’s present experience in a non-judgmental manner.17 As interrupting thoughts enter
the mind, the MFL meditator acknowledges them and returns his or her focus to the
meditation object.18 In this study, we employ concentration mindfulness, where the
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subject focuses on their breath, with a goal on awareness of the present moment. Studies
have shown mindfulness meditation to be effective in the treatment of pain, addiction,
anxiety, and depression.19
Zeidan et al. 2010 used a brief MFL meditation intervention in 24 college students
and controlled with a book-listening activity for 25 matched controls.18 After four 20minute sessions of MFL training (one per day over four days), the MFL group had
significantly improved scores on Symbol Digit Modalities Test, verbal fluency, hit runs
on n-back task, and measures of anxiety and fatigue. They did not find significant
differences on mood scales of depression, anger, confusion, or vigor, forward or
backward digit spans, or speed n-back task, and attributed this possibly to the short
duration of intervention. While the mood scale scores improved, they did not reach
significance. These results suggested that a brief MFL intervention successfully improved
neuropsychological testing scores, but raised the possible confounder that the control
book-listening group was perhaps equally relaxing to MFL meditation, and thus possibly
prevented results from reaching statistical significance on other mood scores. Toneatto
and Nguyen 2007 published a review article that supported these concerns, and suggested
that MBSR techniques are not more effective than active control groups, such as
relaxation, when compared to an inactive control.20 The Zeidan et al. 2010 results are
limited in applicability to our proposed study due to the average age of subjects (20 years
old), and they are cognitively healthy. However, these results support our study in several
ways.18 First, they found significant effects over a short intervention period (four
sessions) of training and reported no adverse events. Also, their suggestions further
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support the use of our inactive and active control group as a way of controlling for the
possible confounding effects produced due to a cognitively active control group.
A recent randomized trial by Smart et al. 2016 studied participants with (n=22)
and without (n=14) subjective cognitive impairment.21 MFL was operationalized
similarly to MBSR protocols, using eight, weekly, two-hour group sessions and home
meditation practice along to a CD. Psychoeducation served as the active control, and met
five weekly two-hour sessions. In this group, participants learned about cognitive decline
and aging. The researchers noted that these timelines were established protocols for
MBSR and psychoeducation interventions, and thus the three-week difference should not
cause confounding effects. One conclusion drawn from the study was that MFL
participants had improved moment-to-moment attention. Improved attention was
suggested to potentially help both cognitively health and subjects with cognitive
impairment delay or slow future decline through better regulation of attention, which
could possibly help retain newly learned information. One limitation to this study is that
not all subjects with subjective cognitive impairment progress to aMCI or AD. The
authors also cite restricted power due to small sample size, though the study was a pilot.
Several meditation studies have focused the effects of meditation on attention and
concentration, which are crucial components of working memory and executive function.
Tomasino et al. 2016 showed that an eight-week MFL, for 30 minutes, four times per
week, intervention in 13 cognitively healthy adults had significant effects on activation of
the right dorsolateral PFC, anterior insula, and left caudate; all areas important for
focused attention.22 Also, they found deactivation in DMN areas that are typically
activated during mind-wandering, such as the rostral PFC and right parietal area 3b, with
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increased activation in the dorsolateral PFC, an area important for attention and
concentration. While these subjects were cognitively healthy adults, the results suggest
meditation can reduce activity in areas associated with mind-wandering and improve
concentration. Pre-intervention fMRIs allowed subjects in this study to serve as their own
control, which is one limitation of this study, in addition to its small sample size of 13.
IV. Experienced Meditators
Garrison et al. 2015 showed that experienced meditators (n=20) have decreased
activity on fMRI in DMN during meditation and rest, compared to meditation-naïve
controls (n=26).23 This study is limited in applicability to the proposed study because of
younger mean subject age (44) without memory complaints. Brewer et al. 2011 also
found that experienced meditators have decreased activation at rest of the posterior
cingulate cortex and medial prefrontal cortex on fMRI.17 These results collectively
support the longevity of the effects of meditation on key DMN areas.
Pagnoni et al. 2008 studied differences in word and non-word identification
between 12 experienced Zen meditators and 12 matched naïve meditators.24 In between
tasks, all subjects were instructed to focus on their breath, a task similar to mindfulness
meditation. While there was no significant difference in reaction time or errors,
meditators showed decreased BOLD fMRI signals, reaching even to below baseline
between tasks. Pagnoni et al. suggested the experienced meditators are able to prevent
mind-wandering that occurs between tasks compared to the controls. In concordance with
prior literature, the researchers concluded that meditation practice allows for regulation of
spontaneous mental activity. They suggest that experienced meditators are more efficient
at refocusing their attention between tasks, and are therefore better at task switching than
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non-meditators. The researchers point out that due to the difference in position (supine
vs. seated) in the scanner and how a subject normally meditates could have prevented
differences in reaction time and performance between groups. Limitations of this study
include its cross-sectional design, and its small sample size despite being powered with
the sample size it used. It is limited in generalizability to our study as well because the
participants are cognitively healthy.
V. Meditation on Depression and Anxiety
The DMN modulates many intrinsic and self-related processes such as mindwandering, day dreaming, and rumination, and is most active at rest and during
autobiographical tasks in cognitively normal people.3 Increased mind-wandering has been
associated with decreased performance on cognitive tests, and rumination is linked to
anxiety and depressive symptoms.18 Depression, apathy, and social withdrawal are
hallmark symptoms of AD, and negatively impact quality of life of the individual as well
as the caregivers and family members.25 In a study by Geda et al. 2004, more than half of
people with aMCI scored significantly higher than age matched controls on measures of
anxiety and depression.26 Depressive symptoms are also found to be independent risk
factors for both aMCI development and progression to AD. These and other mood
symptoms occur significantly more in people with aMCI compared to age-matched
controls with normal cognition. While research on the temporal relationship between
depression and anxiety and aMCI is limited, higher depressive symptom scores have been
associated with poorer baseline memory, and greater decline of memory testing scores in
a five-year period amongst elderly participants.27 These not only impact quality of life,
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but also suggest that depression is related to poorer memory functioning. This
exacerbation of cognitive impairment may hasten decline.
Feldman et al. 2004 found 59% of subjects with aMCI (n=1,010) suffer from
neuropsychiatric symptoms, most commonly depression, anxiety, and irritability.28
Additionally, the presence of these symptoms correlates with increased aMCI severity
and functional impairment, and increased risk of progressing to AD. Decreasing
symptoms of anxiety and depression in these patients through meditation would have
important effects not only for their quality of life, but also potentially partially protect
against disease progression.
Several studies have shown that meditation can improve anxiety and depressive
mood symptoms. Goyal et al. 2014 conducted a meta-analysis of meditation literature in
cognitively normal subjects and found MFL had moderate supporting evidence of
improved anxiety, depression, and pain ratings after eight weeks of meditative practice.19
This review lends support that an eight-week MFL intervention could show an effect that
reaches significance on mood measures of anxiety and depression.
Moss et al. 2012 employed a small, randomized clinical trial using an eight-week
KK meditation compared to a music listening control.29 Fifteen subjects, with varying
degrees of memory complaints, either meditated or listened to music for 12 minutes a day
for eight weeks. Subjects were pre-imaged with SPECT to examine cerebral blood flow
and given a neuropsychological battery was given of a category fluency test, Wechesler
Adult Intelligence Scale Substitution Test, Logical Memory, and TMT A and B. After the
intervention, subjects were reimaged and given the same neuropsychological tests.
Additionally, they used the Profile of Mood States questionnaire to examine subjects’

24

feelings of tension, depression, anger, fatigue, and confusion. The meditation group
showed improvement in all measures on the Profile of Mood States, but only fatigue
reached significance. This study had several limitations, including small sample size of
15 and varying degrees of memory impairment, leading to a less homogeneous aMCI
population. For example, seven of their subjects had age related memory impairment. A
more homogenous population could have improved validity and potentially led to
different results.
Lavretsky et al. 2013 examined the effects of an eight-week KK intervention on
mental health, depressive symptoms, cognition, and telomerase activity in caregivers with
mild depressive symptoms.30 These 39 caregivers were all caring for people with aMCI,
AD, or other dementia, and mean age was 60.3. After the eight-week KK intervention,
they found an improvement in mental health ratings, specifically depression, as rated by
the Hamilton Rating Scale for Depression (65.2% in KK group vs. 21.2% in relaxation
group) and the Short Form (36) Health Survey (52.2% KK group vs. 18.7% relaxation
group). They also found statistically significant improvements on the Trails B Test and
Mini Mental Status Exam (MMSE) after KK intervention, supporting meditation’s effect
on executive function and overall cognition. Improvements were noted in the Trails A
and CVLT tests mean change from baseline, but did not reach significance.
This study also examined immune cell telomerase activity, which correlated with
decreased levels of depression and improved mental health score in the KK group.30 They
found 43.3% improvement in the KK group, reaching significance compared to 3.7%
improvement in the relaxation group. Immune cell telomerase activity is inversely
correlated with levels of chronic stress, and the researchers concluded that meditation is
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able to specifically improve telomerase activity, cognition, and mental functioning, while
significantly decreasing depressive symptoms. Limitations of this study include small
sample size, and lack of cognitive deficits in the study population, which limits
generalizability to our study’s population.
VI. Music Listening as an Active Control for Meditation
Music listening will serve as this study’s active control group, which is consistent
with the majority of literature involving an active control. KK studies that do not use
music listening often use audiotaped book listening as their control.18 Because our
primary outcome is verbal memory, we chose not to use book listening to prevent
possible confounding effects attributed to listening to words.
The Moss et al. 2012 study compared meditation-naïve subjects undergoing an
eight-week KK meditation intervention to subjects who listened to 12 minutes of Mozart
violin concertos.29 In the Newberg et al. 2010 study described above, a second
comparison group was added (n=5) that listened to Mozart violin concertos for 12
minutes/day for eight weeks.31 Neither study found significant differences in pre and post
testing on measures of executive functioning or working memory in the music listening
groups. However, they did not reach significance on several of their outcomes, which
could be due to effects of music listening. For example, music therapy has been shown to
improve verbal fluency in patients with dementia.16 Newberg et al. 2010 suggested the
future use of an inactive control group for the music listening group to mitigate these
effects. The proposed study aims to mitigate these possible effects by adding a wait list
control.
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VII. Limitations with Current Literature
The purpose of this study is to compliment and expand the current literature on
meditation in aMCI. Studies reviewed had small sample sizes, and thus were subject to
underpowered results and null findings. Given the large number of subjects with aMCI in
the US, we believe recruiting a larger sample size is feasible within the Yale Memory
Clinic or Yale Alzheimer’s Disease Research Center.
An additional limitation of the current literature surrounds the selected studies’
control groups. Controls for the studies reviewed are either active (relaxation or
book/music listening) or inactive, but to our knowledge no studies have used both. We
aim to use both a music listening control and an inactive group to control for the possible
benefits of music listening. For example, Ray and Mittleman 2015 found that two weeks
of music therapy significantly improved depression and agitation symptoms in nursing
home residents with dementia.32 We believe that previous studies that did not include a
waitlist control could have had their significance obscured or minimized by the effects of
music listening, or other cognitively active control situations on the subjects, hence
possibly obscuring effects of meditation.
KK and MBSR are the predominantly used meditation interventions in the
literature. MBSR was not chosen for our study because it requires more hours of practice
and a weekly group meeting,33 making it too dissimilar to our KK intervention. A major
conflict of interest exists with studies solely focusing on KK interventions, because the
Alzheimer’s Research and Prevention Foundation, which provides funding for many of
these studies, promotes KK meditation. The Alzheimer’s Research and Prevention
Foundation sells KK meditation CDs, MP3 files, and offers free practicing material on
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their website, and supported the Newberg et al. 2010, Lavretsky et al. 2012, Moss et al.
2012, Black et al. 2013 and other studies. This study aims to add the MFL group to
potentially provide another meditation intervention for clinicians to introduce to patients.
Finally, Newberg et al. 2010 suggested future studies employ larger samples, more
groups, and a larger number of outcome measures,22 which the proposed study aims to
address.
VIII. Primary Outcome—Verbal Memory
The primary outcome variable is percent change from baseline performance on
measures of verbal memory, operationalized by the CVLT-II, a well-validated and widely
used test used to measure episodic memory in subjects with aMCI22,34 and suggested by
Albert et al. 2011 for use in diagnostic and research outcomes in populations with
aMCI.34 The CVLT-II is designed to test verbal episodic memory functions including
encoding, delayed recall, and recognition.35,36 It takes 20 minutes to administer followed
by a delay of 30 minutes to examine delayed recall.37 The encoding phase consists of
reading a list of 16 words over five trials. Next, an interference list of words is read to the
patient that they then recall followed by immediate and delayed recall of the first list and
a yes/no recognition paradigm. Subjects will be randomly assigned to take the standard or
alternate version to reduce practice effects.9 Subjects will take the other version at eightweek follow up.
The CVLT-II is a well-validated and widely used test used to measure episodic
memory in subjects with aMCI.22,34 When compared with three other verbal memory tests
using multivariate Cox regression analysis, CVLT-II is predictive of aMCI conversion to
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AD.7 Additionally, Wang et al. 2013 found a positive association between the CVLT-II
and DMN dysregulation.9
IX. Secondary Outcomes
While the diagnosis of aMCI relies on subjects’ impairments in episodic memory,
aMCI is known to be associated with multiple domains of cognition.3 Secondary outcome
variables are designed to measure the effect, or lack of effect of these interventions on
measures of verbal fluency, working memory, executive function, depression and
anxiety. These will be measured with category fluency, letters C, F, and L fluency, TMT
A and B, WAIS-IV Digit Span Test, RAID, and GDS. Percent change from baseline
performance will be measured to determine differences in pre and post intervention
testing. Albert et al. 2011 suggested these tests be used in populations with aMCI to
examine deficits in cognitive domains outside of episodic memory.34
IX.a Verbal Fluency
Measures of phonemic (C, F, L) and semantic (animal) verbal fluency are
validated and commonly used measures of verbal fluency in cognitively impaired adults
including those with aMCI.6,22 As discussed previously, Mueller et al. 2015 found that
people with aMCI have lower scores on both of these measures compared to cognitively
healthy subjects.6 While diagnostically useful to differentiate normal aging from aMCI,
these also represent a word finding deficit many patients with aMCI encounter from early
stages of their disease process. Animal naming reflects semantic fluency while Letter C,
F, and L naming reflects phonemic fluency. Semantic fluency is thought to be more
impaired in subjects with aMCI due to greater impairment of semantic categorization
compared to phonemic fluency.
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IX.b Working Memory
The WAIS-IV Digit Span Test is a measure of working memory that includes
attention, encoding, and mental flexibility.3,14 It has been used as an outcome in
meditation studies in people with aMCI previously.16 Subjects repeat increasingly long
sequences of digits beginning with practice trials increasing to nine digits forwards and
backwards. For this study, the measure is determined by the difference between the
scores for sequencing forwards and backwards digit spans.
IX.c Executive Function
Trail Making Tests A and B are measures of mental flexibility, and also examine
set-shifting ability, both features of executive functioning.3,14 Trail Making Test A
requires subjects to connect circles with numbers 1-25 as fast as possible. Trail Making
Test B is more difficult, and subjects must connect a sequence of numbers and letters in
the following pattern: 1-A-2-B-3-C. This study will use the difference in time to
completion of tests A and B as the outcome measure. This scoring technique for the Trail
Making Tests has been found to have 64% sensitivity for predicting conversion of MCI to
AD, and is therefore sensitive to the changes that are specific to aMCI.38 Newberg et al.
2010 also found a correlation between improved Trails B time and increased PFC
cerebral blood flow on SPECT imaging in the KK meditation group.16
IX.d Anxiety and Depressive Symptoms
The RAID and GDS are measures of anxiety and depressive symptoms,
respectively, tailored for use in the elderly population. These measures are used as
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screening tools to evaluate elderly subjects with anxiety or depressive symptoms,10 and
also as markers of mood symptoms as they change over time.9
X. Justification for Study Design
Study population, including exclusion and inclusion criteria, is sourced from the
literature.10 Our study population inclusion criteria will consist of patients aged (1) 65-85
with an MMSE score  26,21 (2) who meet Petersen criteria for aMCI,39 (3) have SPECT,
PET, or MRI imaging suggesting or consistent with AD pathology,34 (4) proficiency with
English language,24 and (5) have at least a high school diploma. Exclusion criteria
includes (1) prior traumatic brain injury (TBI),3,9 (2) prior cerebral vascular accident
(CVA),3 (3) comorbid psychiatric, medical, or neurological conditions,9,10 (4) alcohol
abuse,13 (5) prior/current brain neoplasms,10 (6) projected <1 year life expectancy, (7)
prior meditation experience >1 year, (8) concurrent enrollment in another study. These
criteria and projected power of the study aim to create a population that can be
generalized to people living in the Northeast United States with aMCI, while reducing
confounding variables that could affect outcome measures.
Our subjects will be randomized to the four groups. While other studies have
used age- matched controls,10 or matched we aim to reduce subject bias and enhance
internal validity through randomization. Adherence will be ensured using a daily log of
adherence to practice similar to the procedure of Lavretsky et al. 2012,30 and an
additional weekly phone call to check in on compliance for the MFL, KK, and music
listening groups.
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XI. Statistical Methods
XI.a Sample Size
Small sample size is a common limitation to the current literature on meditation
interventions in cognitive impairment. This study’s sample size calculation was derived
from the Moss et al. 201230 and Newberg et al. 201016 studies described previously. Moss
et al. 2012 used 15 subjects with varying degrees of memory problems in an eight-week
KK intervention, and derived statistical significance on several parameters.29 The
Newberg study used three populations with differing levels of cognitive impairment, with
total 14 subjects, also reaching significance on several outcomes.22 Both studies cited
small sample size as major limitations, and subjects groups had less than eight subjects
per group. Data from the Newberg et al. 2010 study were used to determine effect size
and sample size. Effect size () was calculated at 11. The PS: Power and Sample Size
Version 3.1.2 software, an -value of 0.05, power of 80%, a  of 6.3 (conservative
estimate), and m=1 for the independent t-test, generated an initial n=24 (Appendix C).
After Bonferroni Correction, to control for multiple comparisons, the sample size was
adjusted to n=40. A conservative 25% drop out rate,22,30-31 increased the number to n=50.
To make the groups even, the total number of participants was increased to 52, to make
four groups of 13.
XI.b Statistical Tests
Outcomes will be measured as percent change from baseline, which is consistent
with the Newberg et al. 2010 study.16 Significance will be 0.05 for all tests. Consistent
with several studies of cognition after meditation intervention, we will use a withinsubjects repeated measures multivariate analysis of covariance (MANCOVA) for the
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CVLT-II, phonemic and category naming, TMT A and B, WAIS-IV Digit Span Test,
RAID, and GDS as dependent variables.18,30 Age, gender, MMSE, and education level
serve as covariates in this model for each outcome. A MANCOVA analysis will help
protect against Type I errors, compared to multiple ANCOVA analyses. A paired T-test
cannot be used, because the study is designed with more than two groups, unlike the
Moss et al. 2012 and Newberg et al. 2010 studies, which used only two groups. While
participants will be randomized, statistical corrections will be performed if baseline
characteristics of age, gender, MMSE, and education level between groups significantly
differ, which could affect the results. Post-hoc tests will be performed as needed to
examine possible interactions from all model outcomes. IBM SPSS Statistics will be used
with a general linear model for a within-subjects repeated measures analysis.
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CHAPTER THREE—STUDY METHODS
I. Study Design
This study is a prospective, single center, randomized clinical trial to study two
interventions, Kirtan Kriya and Mindfulness meditation, on measures of verbal memory,
specifically semantic categorization, compared to music listening and wait list controls.
Secondary outcomes include measures of verbal fluency, executive function, working
memory, anxiety, and depression. Percent change from baseline scores within groups is
the outcome measure. Participants will be computer randomized into KK, MFL, music
listening, or wait list groups so baseline characteristics are not statistically different.
II. Study Population and Sampling
52 community-dwelling male and female patients will be recruited from Yale
Memory Clinic and Yale Alzheimer’s Disease Research Center. See Table 1 for inclusion
and exclusion criteria. Randomization aims to create groups so that baseline
characteristics between groups will not be statistically different, but if groups
significantly differ, demographic variables (age, MMSE score, education level, gender)
will be adjusted for in post-hoc statistical analysis.
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Inclusion Criteria

Exclusion Criteria

Age: 65-85

Prior TBI7,8

Diagnosis of aMCI1

Prior CVA3

Imaging consistent with neuropathological findings of AD2-6

Comorbid conditions7,9

English proficiency

Concurrent enrollment in other study

MMSE score  26

>1 year meditation experience

High school education

Alcohol abuse13
Prior/current brain neoplasms9
<1 year life expectancy

Table 1. Inclusion and Exclusion Criteria
III. Subject Protection and Confidentiality
The Yale Human Investigation Committee (HIC) will approve the study, along
with HIC approval. Prior to enrollment, volunteer participants will sign an informed
consent form (Appendix D). This form contains information explaining the potential
benefits, risks, and reasons for performing the study, as well as a timeline of the trial. It is
clearly stated that participation is voluntary, and a participant is free to discontinue
participation at any time. Participants will not be compensated for their participation, and
will not be charged for clinician visits pertaining to the study. All employees involved in
the study will complete HIPAA training certification and Human Subjects Protection
training. Additionally, the Yale HIC will approve all study materials including consent
forms and any study flyers or announcements.
All patient information will be used exclusively for this research study, and will
be maintained according to guidelines set forth by HIPPA and the United States
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Department of Health and Human Resources. Printed material will be secured in a filing
cabinet at the researcher’s office in New Haven, CT accessible only to study researchers.
Digital information will be stored on an encrypted and password-locked computer that is
only accessible to the Lead Investigator. Each patient will receive a computer generated
random 10-digit code to replace his/her identifying information. The data will only be
identifiable by code to investigators involved.
IV. Recruitment
Recruitment will last six months prior to initiation of the study. Patients will be
recruited through clinician recommendation from the Yale Memory Clinic and selfreferral through flyers and advertisements posted around Yale New Haven Hospital
System (Appendix E). Clinician referral will attempt to decrease selection bias caused by
self-referral through advertising. After a patient is referred, a research assistant will call
the patient to explain the opportunity to participate in a research study. If interested, an
appointment of approximately one hour will be scheduled to conduct baseline assessment
following the six-month recruitment period and group randomization. At this
appointment, participants will be formally enrolled, perform baseline testing, and learn
their intervention if applicable.
We aim to yield a larger total study population to increase the power of our
results, as lack of power has been a significant problem with previous studies exploring
meditation in MCI and AD. While other studies of subjects with aMCI employed groups
with an average total number of 13 participants, we aim to have 13 participants in each
arm of the study, which is larger than other meditation studies exclusively focusing on
subjects with aMCI.
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V. Study Variables and Measures
We will employ two meditation interventions, one active control, and one wait list
control. The meditation interventions will be KK and MFL. The active control will be
music listening, and the wait list control will have no further intervention. Participants in
the KK group will watch a ten-minute instructional video on how to practice KK
meditation, and then show a researcher how to perform the meditation to demonstrate
proficiency. They will be given Appendix A as a visual aid and a CD of guided KK
meditation to listen to for 12 minutes/day for eight weeks at their convenience.
Participants in the MFL group will watch a ten-minute instructional video on how to
practice MFL meditation, and teach back the instructions to a researcher to demonstrate
proficiency. They will return home with Appendix B and a MFL guided meditation CD
to practice 12 minutes/day for eight weeks. Participants in the music control group will
listen to Wolfgang Amadeus Mozart concertos for 12 minutes/day for eight weeks
consistent with the protocols by Moss et al. 20121 and Newberg et al. 2010.2
The primary outcome is percent change from baseline scores on measures of
episodic memory using the CVLT-II, specifically verbal recall (total, immediate, and
delayed) and semantic categorization. Secondary outcomes include percent change from
baseline scores on Animals Fluency and Letters C, F, L Fluency measuring semantic and
phonemic fluency, respectively, as well as WAIS-IV Digit Span Test, TMT A and B,
GDS, and RAID Scale to assess working memory, executive function, and symptoms of
depression and anxiety.
VI. Blinding of Intervention/Outcome
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Due to the nature of the interventions, the study will not be completely blinded.
The researcher responsible for distributing the computer-generated randomizations will
be blinded. A blinded researcher will conduct the pre and post neurocognitive test
administration and subsequent data collection and analysis, identifiable only by the 10digit code. Due to the nature of the study, the participants will not be blinded to their
intervention. A non-blinded researcher will ensure intervention performance competence
and call participants weekly. This researcher will also be responsible for answering the
emails and calls of patients. This researcher will not be a part of data collection or
analysis.
VII. Assignment of Intervention
Patients will be randomized to one of the four groups at the end of the 6-month
recruitment period. Possible confounding baseline variables include age, gender, MMSE
score, baseline test performance, and education level. An analysis will be performed to
examine for group differences. If significant, these demographic variables will be
adjusted for in the statistical analyses.
VIII. Data Collection
Following the recruitment and enrollment period, participants will perform
baseline neuropsychological testing of the CVLT-II (total recall trials 1-5, immediate
recall, delayed recall, semantic categorization), WAIS-IV Digit Span Test, Categories
(Animals) and Letter C, F, and L Fluency, TMT A and B, GDS, and RAID scale. Next,
they will undergo training for the intervention, followed by teach back for the meditation
groups. At the eight-week follow up visit the tests will be re-administered. After
intervention is complete, patients may keep the meditation or music CD. Data will be
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identifiable only by the 10-digit code assigned to each participant. A blinded research
assistant will enter the test scores into the encrypted computer database.
IX. Adherence
The participants will be provided with a daily diary to record the time they
performed the intervention each day to ensure adherence. A researcher will call the
patient within the first five days, and then weekly to ensure compliance with the
intervention. Participants will be given a phone number and email address of the nonblinded investigator to contact with questions at any time. Wait list participants will not
be contacted.
X. Monitoring Adverse Events
Clinicians not involved in the research will monitor for adverse events, however,
these are atypical in meditation studies. Researchers will monitor for adverse or
unexpected experiences, which could include depression, anxiety, boredom, confusion,
and disorientation according to one study reporting the negative possible effects of
meditation.3 If an adverse experience occurs, the participant may withdraw from the
study at any time.
While the study has several measures to ensure privacy and data protection, an
unintended release of information or hack of medical information is still possible, and
will be promptly managed with assistance from the Yale Information Technology
Services. In such an event, participants will be notified promptly of the release of their
medical or other sensitive information.
XI. Sample Size Calculation
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Sample size calculation was performed using PS: Power and Sample Size Version
3.1.2 software. Sample size calculation has been estimated to be n=52, with 13
participants per group. This number was based on the study by Newberg et al. 2010,2
which also determined a power () of 11 and standard deviation difference (conservative
estimate, ) of 6.3. Initially with a type 1 error of 0.05 (), the calculation yielded six
participants per group (total n=24), however the Bonferroni Correction estimate increased
the calculation to total group size of 40. This number was adjusted to account for a 25%
drop out rate, consistent with the literature,2,4,5 ultimately yielding 13 participants per arm
of the study, and total of 52 subjects. This study’s sample size is larger than previously
published similar studies whose results lacked power due to small samples.1,6
XII. Timeline
The study, including analysis, writing, and publication submission, will be
completed within the 24-month deadline, starting June 30, 2016 with patient recruitment.
The actual study, from enrollment to completion of follow up testing, will take nine
months. See timeline below (Figure 1). Patients will be enrolled during the first
appointment. Following the 6-month recruitment period, participants will be called back
for baseline testing and to learn their intervention for the KK, MFL, and music listening
groups. Wait list groups will be brought back for baseline testing only. The order of the
tests will be: CVLT-II Short Recall, WAIS-IV Digit Span, Trail Making Test A and B,
CVLT-II Delayed Recall, Animal Naming, and Letter C, F, L Fluency. Data collection
and analysis will occur immediately following the post testing.
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Recruitment
(6 months)

Baseline Testing and
Intervention
Assignment
(All Participants, over 2
week period)

Intervention
(8 weeks)

Post Testing
(All participants, over 2
week period)

Figure 1. Timeline

XIII. Resources
We will have a secure computer for data entry and code generator to produce the
patient’s secure number code. The data will be stored on an external hard drive. The
computer and external hard drive will be passcode protected. The passcodes must be
changed every 6 months. The hard copies of the tests and baseline demographic sheet
will be stored in folders identified with the patient’s numerical code in a locked filing
cabinet. All other identifying information will be removed. A secure office in the Yale
Memory Clinic will be used to conduct the neuropsychological testing.
The instructional videos on the meditation will be delivered on a computer that
can access YouTube. Compact discs will be given to the patients in the three active
groups containing the audio recording of their guided meditation or music. Participants
without a portable CD player and/or headphones will be given them. Funding for these
materials will come from the grant.
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CHAPTER FOUR—CONCLUSION
I. Advantages and Limitations
Our study poses several advantages to previous studies, and aims to expand upon
the current literature on meditation interventions in aMCI. First, we will use an inactive
and active control group. Control group choice is a difficult aspect of research design in
this field, and many studies have attempted to mitigate problems associated with one type
of control group. For example, studies only using an active control could have trouble
reaching significance because the control activity could also cause changes in cognition
or brain activity on imaging. While studies using this control method cite this as a benefit
to determine the unique cognitive effects of meditation, it is also a disadvantage, as we
have previously described benefits of music listening in elderly people with memory
complaints.
Studies that only use an inactive control group have difficulty attributing all of
their findings to meditation alone, instead of the effect of introducing any intervention to
a subject with aMCI. Known benefits of performing an intervention could include subject
bias of expecting an effect after performing the intervention, but could be expanded to
possible benefits gained by performing a daily routine, subjective feelings of purpose as a
participant in a study, access to significant relationships, all found to improve quality of
life in senior citizens.1 For example, subjects in the MFL intervention and
psychoeducation intervention in the Smart et al. 2016 both self-reported improved
memory, cognition, and no significant difference on measures of depression between
groups.2
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Another advantage to our study is the specific inclusion and exclusion criteria to
make a homogenous population. Previous studies used participants with varying degrees
of cognitive impairment, or AD and aMCI, or had a diagnosis of aMCI that was only
clinical. This study will solely focus on subjects with aMCI as diagnosed by clinical
data3,4 and neuroimaging suggestive of AD neuropathology.5 We exclude a variety of
confounders including prior stroke, alcohol abuse, malignancy, or prior traumatic brain
injury. These exclusion criteria are consistent with the literature, and combined with the
specific inclusion criteria will likely lead to a more homogenous aMCI sample. This
sample population will also be much larger than previous studies, with the aim of
achieving larger effect sizes.
The purpose of this study is to examine the effectiveness and feasibility of two
interventions on cognitive outcomes, but it does not include neuroimaging as an outcome.
In follow-up studies, we intend to use information gained from this study to design a
study that would examine the effects of meditation interventions on the DMN with
neuroimaging, as well as enlarge the neuropsychological testing battery. However, this
study will require less funding because it does not include imaging, which is beneficial
for a preliminary study. Another future direction could examine the longevity of the
impact of meditation on the brain, and could provide more information on disease
progression within the aMCI population throughout all of our participants.
Another limitation to this study is using a relatively large number of outcomes
with several neuropsychological tests, which lends the possibility of finding effects
reaching significance on chance alone, especially in the setting of our relatively small
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sample size. The Bonferroni Correction was used to mitigate this effect, but it still poses
a threat to validity.
This study will recruit participants partially through self-referral, which
introduces the possibility of subject bias. We are hoping to mitigate this effect with
randomization of participants and physician referral for recruitment, but the threat still
exists. It is impossible to blind our participants; therefore knowledge of group could
affect participants’ subsequent testing and reporting of mood symptoms. We aim to
address this by treating groups as equally as possible, and blinding the investigators
involved with data analysis. We also have a dedicated researcher who is non-blinded who
will perform the follow-up phone calls, and will not be a part of data analysis.
A final limitation to any study involving meditation is that it is inherently difficult
to ensure true compliance. This study has several measures in place to ensure adequate
compliancy, including a teach back for proficiency, weekly compliance phone calls, and
a daily log to ensure proficiency and compliance, but ultimately it is difficult to ensure
participants are putting effort into meditation during the practices. However, the
voluntary nature of our study will hopefully protect against this, since participants are
choosing to be involved.
II. Clinical and Public Health Significance
II.A Economic Impact
People with AD become increasingly dependent on others for basic tasks like
driving and paying bills, but ultimately progress to relying on caretakers for all activities
of daily living, including feeding, bathing, and dressing.4 AD and other dementias are
estimated to cost the United States $226 billion in 2015 for the hospitalization, long-term
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facilities, and hospice care for people with dementia. In 2050, this cost is projected to
increase to $1.1 trillion.
Before institutionalization, many people with AD are cared for in their home or a
family member’s home.6 Often, their caregivers are family members, usually females
(66%) with college degrees (40%). They are rarely compensated for their work, and cite
caregiving as their primary barrier to gaining other employment. Last year, 15.5 million
people provided 17.7 billion hours of unpaid care, valued at $220.2 billion.4 These
caregivers are unable to participate in the paid workforce, leaving them economically
disadvantaged. The recently published 2016 Facts and Figures from the Alzheimer’s
Association reports that 48% of caregivers’ families report the costs associated with
providing for their loved one affects their ability to pay for basic needs.4 While the
burden is largely on spouses and daughters, it is also estimated that 250,000 children age
eight to eighteen provide care for a family member with AD.
Importantly, a one-year delay of AD development from aMCI would result in
nine million fewer cases by 2050.4 This would also lessen caregiver burden, as it would
increase the amount of time the patient is capable of performing tasks independently.
This would have significant impacts on quality of life for the individual, and decrease
costs and burden on the healthcare system, economy, and caregivers.
II.B Morbidity and Mortality
While most people diagnosed with AD die within a decade of diagnosis, many live
for much longer after initial memory complaints emerge.2 AD is ranked as the 12th most
burdensome disease in respect to reducing a person’s healthy and disability free years. This
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number has increased drastically since 1990, when it was the 25th most burdensome
disease.
The Alzheimer’s Association estimates that 61% of people over the age of 70 with
AD will die before age 80.2 In contrast, people over the age of 70 without AD have a 30%
risk of death before 80. Additionally, deaths attributed to AD, meaning they were unlikely
to have occurred without the presence of AD, has increased 71% since 2000. While this
increase could be related to an increase in citing AD as cause of death on death certificates,
it is notable both in regards to disease burden and the incidence in the growing aging
population.
III. Importance of the Proposed Study
Our proposed study targets a population with amnestic mild cognitive
impairment, which is a frequently used group for interventions to slow cognitive decline
and delay institutionalization.6 As described previously, delay of institutionalization by
only a year relieves an enormous economic burden on the health care costs within the
country’s rapidly growing elderly population.2 Additionally, quality of life is closely
associated with a person’s independence, and perceived to decrease upon
institutionalization.1
Meditation is a promising intervention studied in the context of many disease
processes.7,8 Materials, if any, are low cost, which benefits both the patient and insurer.
Meditation is associated with minimal risks, and does not have any known negative side
effects. After the practice is learned, meditation can be used at any time or place and
requires no additional materials. Meditation is additionally advantageous compared to
other non-pharmaceutical interventions especially in aging populations, because unlike
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exercise or yoga, it requires none or very little physical abilities. This is important in the
context of an aging population whose physical limitations advance with age and disease
state. For KK meditation, one must only move their fingertips, while mindfulness does
not require any purposeful movements. MFL provides an additional advantage, as it
could be more appealing to an elderly demographic who could be averse to practicing a
chanting meditation. From a caregiver’s perspective meditation is an ideal intervention
because the patient can perform it completely independently and at their leisure, with no
supervision or set up required.
We designed this study to have a primary outcome on measures of verbal
memory, a facet of episodic memory, because it is typically the first aspect of cognition
impaired in people with aMCI.9 We believe that if we focus on the first affected aspects
of cognition, we will hopefully enable us to see the greatest improvements with an
intervention. We aim to possibly help people slow their cognitive decline through
meditation, build compensatory capabilities, reduce the expression of the disease and
other domains of cognition including attention, processing speed, and executive
processes, and possibly find a way to mitigate the DMN dysfunction found in aMCI.
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APPENDIX A: Kirtan Kriya Meditation Instructions
1. Repeat the Saa Taa Naa Maa sounds (or mantra) while sitting with your spine straight. Your
focus of concentration is the L form, while your eyes are closed. With each syllable, imagine
the sound flowing in through the top of your head and out the middle of your forehead (your
third eye point). Start the CD when you are ready. It will cue your transitions.
2. For two minutes, sing in your normal voice.
3. For the next two minutes, sing in a whisper.
4. For the next four minutes, say the sound silently to yourself.
5. Then reverse the order, whispering for two minutes, and then out loud for two minutes, for a
total of twelve minutes.
6. To come out of the exercise, inhale very deeply, stretch your hands above your head, and
then bring them down slowly in a sweeping motion as you exhale.
The mudras, or finger positions, are very important in this kriya (see illustration below).

•
•
•
•

On Saa, touch the index fingers of each hand to your thumbs.
On Taa, touch your middle fingers to your thumbs.
On Naa, touch your ring fingers to your thumbs.
On Maa, touch your little fingers to your thumbs.
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APPENDIX B: Mindfulness Meditation Instructions
1. Sit in a comfortable position with spine straight.
2. Focus your concentration in an L form (see Illustration below) with your thoughts
entering through the top of your head, and exiting through your mouth on
expiration.
3. Begin the guided CD, which will lead your meditation for the next 12 minutes.
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APPENDIX C: SAMPLE SIZE CALCULATION

Initial Sample Size: 6 x 4 groups = 24 total participants
• After Bonferroni Correction for multiple comparisons N= 10/group;
total N=40
• Drop Out Rate (25%)= 40 x 0.25= 50
• 50/4=12.5→ 13 participants/group = 52 total participants
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APPENDIX D: INFORMED CONSENT FORM
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT
200 FR. 1 (2014-4)
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL
Study Title: Meditation Interventions in Amnestic Mild Cognitive Impairment
Principal Investigator: Emily K. Richards, PA-S; Emily Sharp, PhD.
Funding Source: Yale School of Medicine
Invitation to Participate and Description of Project
You are invited to participate in a research study designed to examine the effect of a
meditation intervention practiced over 8 consecutive weeks on cognitive outcomes and
measures of anxiety and depression.
In order to decide whether or not you wish to be a part of this research study you should
know enough about its risks and benefits to make an informed decision. This consent form
gives you detailed information about the research study, which a member of the research
team will discuss with you. This discussion should go over all aspects of this research: its
purpose, the procedures that will be performed, any risks of the procedures, and possible
benefits. Once you understand the study, you will be asked if you wish to participate; if so,
you will be asked to sign this form.
Description of Procedures
If you agree to participate in this study, you will be designated to an intervention group, an
active control, or wait-list control group. Those in the intervention groups will learn one
of two forms of meditation to be practiced for 12 minutes/day. The active control group
will listen to a music CD for 12 minutes/day. Those in the intervention and active control
groups will learn and perform their intervention on the same date as baseline testing. The
interventions can be performed from home at a time of your choosing. Weekly phone calls
will be made to your home to ensure compliance with performing the intervention and
answer any questions you have. You will also be asked to record the time of your
intervention on a daily log. At the end of the 8 weeks, you will return to the clinic for follow
up testing. You may keep the materials given to you at the beginning of the program.
Content:
The cognitive tests will measure verbal memory, working memory, executive function,
global cognition, and anxiety and depressive symptoms.
Participation time:
Total length of participation is up to 9 months, however six of those months include the
total recruitment period before the possible intervention begins. If assigned to an
intervention or active control, participation is 12 minutes/day for 8 weeks. The cognitive
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testing is estimated to take 1 hour total, and will occur at the start and end of the 8 weeks.
See Timeline below.

Recruitment
(6 months)

Baseline
Testing

Intervention
(8 weeks)

Post Testing

Risks and Inconveniences
There are no known physical risks associated with this study. However there is the possible
risk of loss of confidentiality. Every effort will be made to keep your information
confidential; however, this cannot be guaranteed.
Benefits
You may learn to perform an evidence-based meditation intervention. Meditation has
been practiced for thousands of years and is associated with many measures promoting
enhanced well-being. Participation in this study may allow researchers to identify a
meditation intervention that may improve cognitive function in people with amnestic
mild cognitive impairment, and potentially slow progression to dementia. This would
allow clinicians to prescribe a cost effective, non-pharmaceutical adjunctive therapy for
their patients that could benefit their function and quality of life as well as delay
institutionalization.
Economic Considerations
No financial compensation is offered in this study. You may keep the materials provided
to you.
Confidentiality
Any identifiable information that is obtained in connection with this study will remain
confidential and will be disclosed only with your permission or as required by U.S. or
State law. Examples of information that we are legally required to disclose include abuse
of a child or elderly person, or certain reportable diseases. All participants will be
identified to researchers as an identification number only. Information obtained
throughout this study and any topics discussed via the online forum will be held strictly
confidential and will be in compliance with the Health Insurance Portability and
Accountability Act (HIPAA) of 1996. Researchers will be required to successfully
complete HIPAA training through Yale University and research information will only be
accessible on encrypted devices that are also password protected. Any physical
documentation that may be created throughout the course of the study will be identified
by the assigned identification number only and will be stored in locked file cabinets in a
secure room on the Yale University campus. When the results of the research are
published or discussed in conferences, no information will be included that would reveal
your identity unless your specific consent for this activity is obtained.
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Representatives from the Yale Human Research Protection Program, the Yale Human
Investigation Committee (the committee that reviews, approves, and monitors research on
human subjects) may inspect study records during internal auditing procedures. However,
these individuals are required to keep all information confidential.
Voluntary Participation and Withdrawal
Participating in this study is voluntary. You are free to choose not to take part in this
study. Refusing to participate will involve no penalty or loss of benefits to which you
are otherwise entitled (such as your health care outside the study, the payment for your
health care, and your health care benefits). However, you will not be able to enroll in this
research study and will not receive study procedures as a study participant if you do not
allow use of your information as part of this study. You do not give up any of your legal
rights by signing this form.
If you do become a subject, you are free to stop and withdraw from this study at any time
during its course. To withdraw from the study, you can call a member of the research
team at any time and tell them that you no longer want to take part. This will cancel any
future appointments. The researchers may withdraw you from participating in the
research if necessary. Developing any of the exclusion criteria may lead to removal from
the study.
Withdrawing from the study will involve no penalty or loss of benefits to which you are
otherwise entitled. It will not harm your relationship with your own doctors or with YaleNew Haven Hospital. If assigned to either control group, you will have the opportunity to
obtain the meditation materials at the conclusion of the study if you so choose.
When you withdraw from the study, no new health information identifying you will be
gathered after that date. Information that has already been gathered may still be used and
given to others until the end of the research study, as necessary to insure the integrity of
the study and/or study oversight.
Questions
We have used some technical terms in this form. Please feel free to ask about anything
you don't understand and to consider this research and the consent form carefully – as long
as you feel is necessary – before you make a decision.
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Authorization
I have read (or someone has read to me) this form and have decided to participate in the
project described above. Its general purposes, the particulars of my involvement and
possible hazards and inconveniences have been explained to my satisfaction. My
signature also indicates that I have received a copy of this consent form.
Name of Subject:_____________________________

Signature:___________________________________
Date:______________________________________
___________________________________________
Signature of Principal Investigator

___________________
Date

or
___________________________________________
Signature of Person Obtaining Consent

___________________
Date

If you have further questions about this project or if you have a research-related problem,
you may contact the Principal Investigator Emily Richards PA-SII (717) 512-4617.
If, after you have signed this form you have any questions about your privacy rights,
please contact the Yale Privacy Officer at (203)-432-5919. If you would like to talk with
someone other than the researchers to discuss problems, concerns, and questions you may
have concerning this research, or to discuss your rights as a research subject, you may
contact the Yale Human Investigation Committee at (203) 785-4688.
THIS FORM IS NOT VALID UNLESS THE FOLLOWING BOX
HAS BEEN COMPLETED BY THE HIC OFFICE

THIS FORM IS VALID ONLY THROUGH:
____________________________________.
INITIALED: _______________________________________
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APPENDIX E: RECRUITMENT FLYER
Research Trial Opportunity

http://www.escapademagazine.com/meditation-more-than-a-trend/

We are recruiting healthy participants, ages 65-85 with amnestic mild cognitive
impairment for a study on meditation
While there is no compensation, you have the opportunity to learn and practice a
meditation for eight weeks in your home, at your convenience.
Meditation is known to help reduce symptoms of anxiety, depression, and improve
thinking ability and concentration.
Contact your clinician to see if you are eligible for this study, or contact Emily Richards
PA-SII —717-512-4617 for more information
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